TY - JOUR
T1 - Favorable outcome in infants with AML after intensive first- and second-line treatment
T2 - An AML-BFM study group report
AU - Creutzig, U.
AU - Zimmermann, M.
AU - Bourquin, J. P.
AU - Dworzak, M. N.
AU - Kremens, B.
AU - Lehrnbecher, T.
AU - Von Neuhoff, C.
AU - Sander, A.
AU - Von Stackelberg, A.
AU - Schmid, I.
AU - Starý, J.
AU - Steinbach, D.
AU - Vormoor, J.
AU - Reinhardt, D.
N1 - Funding Information:
We thank the colleagues, data managers and technicians of the participating hospitals for their valuable cooperation, Jans-Enno Müller for competent data management and Ursula Bernsmann for her help in preparing the manuscript. The studies were supported by the Deutsche Krebshilfe e.V. and partly by grant from the Czech Ministry of Education (MSM0021620813).
PY - 2012/4
Y1 - 2012/4
N2 - Infants <1 year of age have a high prevalence of prognostically unfavorable leukemias and a presumed susceptibility to treatment-related toxicities. A total of 125 infants with acute myeloid leukemia (AML) were treated in studies AML-BFM-98 (n=59) and -2004 (n=66). Treatment regimens of both studies were comparable, consisting of intensive induction followed by four courses (mainly high-dose cytarabine and anthracyclines). Allogeneic- hematopoietic stem-cell-transplantation (allo-HSCT) in 1st remission was optional for high-risk (HR) patients. Most infants (120/125=96%) were HR patients according to morphological, cytogenetic/molecular genetic and response criteria. Five-year overall survival was 66±4%, and improved from 61±6% in study-98 to 75±6% in study-2004 (Plogrank 0.14) and event-free survival rates were 44±6% and 51±6% (P logrank 0.66), respectively. Results in HR infants were similar to those of older HR children (1-<2- or 2-<10-year olds, Plogrank 0.90 for survival). Survival rates of HSCT in 1st remission, initial partial response and after relapse were high (13/14, 2/8 and 20/30 patients, respectively). The latter contributes to excellent 5-year survival after relapse (50±8%). Despite more severe infections and pulmonary toxicities in infants, treatment-related death rate was identical to that of older children (3%). Our data indicate that intensive frontline and relapse AML treatment is feasible in infants, toxicities are manageable, and outcome is favorable.
AB - Infants <1 year of age have a high prevalence of prognostically unfavorable leukemias and a presumed susceptibility to treatment-related toxicities. A total of 125 infants with acute myeloid leukemia (AML) were treated in studies AML-BFM-98 (n=59) and -2004 (n=66). Treatment regimens of both studies were comparable, consisting of intensive induction followed by four courses (mainly high-dose cytarabine and anthracyclines). Allogeneic- hematopoietic stem-cell-transplantation (allo-HSCT) in 1st remission was optional for high-risk (HR) patients. Most infants (120/125=96%) were HR patients according to morphological, cytogenetic/molecular genetic and response criteria. Five-year overall survival was 66±4%, and improved from 61±6% in study-98 to 75±6% in study-2004 (Plogrank 0.14) and event-free survival rates were 44±6% and 51±6% (P logrank 0.66), respectively. Results in HR infants were similar to those of older HR children (1-<2- or 2-<10-year olds, Plogrank 0.90 for survival). Survival rates of HSCT in 1st remission, initial partial response and after relapse were high (13/14, 2/8 and 20/30 patients, respectively). The latter contributes to excellent 5-year survival after relapse (50±8%). Despite more severe infections and pulmonary toxicities in infants, treatment-related death rate was identical to that of older children (3%). Our data indicate that intensive frontline and relapse AML treatment is feasible in infants, toxicities are manageable, and outcome is favorable.
KW - acute myeloid leukemia
KW - children
KW - infants
KW - treatment
UR - http://www.scopus.com/inward/record.url?scp=84859646588&partnerID=8YFLogxK
U2 - 10.1038/leu.2011.267
DO - 10.1038/leu.2011.267
M3 - Article
AN - SCOPUS:84859646588
SN - 0887-6924
VL - 26
SP - 654
EP - 661
JO - Leukemia
JF - Leukemia
IS - 4
ER -